741.0000 -1.50 (-0.20%)
NSE Apr 23, 2025 12:15 PM
Volume: 12,000
 

741.00
-0.20%
KRChoksey
TATVA revenue missed our estimates due to significant decline in SDA segment. EBITDA beat our estimates due to lower-than-expected cost of goods sold and operating expenses. However, Adj PAT missed our estimates significantly due to higher-than-expected depreciation, lower than expected other income.
Tatva Chintan Pharma.. has an average target of 1130.50 from 2 brokers.
More from Tatva Chintan Pharma Chem Ltd.
Recommended